In order to assess the genotoxic effects of antiepileptic drugs (AEDs), analysis of sister chromatid exchanges (SCEs) was performed in lymphocytes of three groups of males ; epileptics with AED therapy, non-epileptics without AED therapy and healthy controls. The epileptics and non-epileptics were cases of severe cerebral palsies due to perinatal asphyxia. Possible confounding factors of SCE frequencies, such as age, smoking habit, drug usage other than AED, recent history of viral infection, etc. were controlled. The frequency of SCE per cell was 4.63+0.71 (mean±s.n.) in epileptics, 4.70+0.89 in non-epileptics and 3.84+0.56 in healthy controls. SCEs in both epileptics and non-epileptics were significantly higher (p <0.05) than those in controls. There was no significant difference of SCE frequency between epileptics and non-epileptics. These results suggested that no mutagenic effect of AED could be demonstrated as revealed by SCEs, and organic brain damage per se might influence the baseline SCE frequency. The possible explanations for such observations are discussed.
Patients with severe organic brain damage are frequently complicated by intractable epilepsy, and long term therapy with two or more antiepileptic drugs (AEDs) is usually necessary. Therefore, these patients may be particularly subject to various adverse effects of AEDs. Among them, genotoxicity of AEDs presents one of the most important medical problems.
Sister chromatid exchange (SCE) involves a symmetrical exchange between two chromatids of one chromosome. Since the original report of Perry and Evans (1975) , SCE has been recognized as a sensitive indicator of DNA damage and repair and widely used not only as a useful in vitro test to assess the mutagenic and 
SUBJECTS AND METHODS
Among about 300 institutionalized brain-damaged individuals, eight epileptic males on long term AED therapy (epileptics) and eight non-epileptic males without AED therapy (non-epileptics) were selected.
All the patients showed the clinical features of cerebral palsy (CP) due to perinatal asphyxia, and those due to congenital malformations of the central nervous system, chromosomal abnormalities, inborn errors of metabolism and sequelae of central nervous system infection were strictly excluded.
All of them were . The blood levels of PHT and/or PB were within the therapeutic range in all the epileptic patients. Epileptic seizure types were bilateral or unilateral tonic seizure and generalized tonic-clonic convulsion. Response to AED therapy was poor except in two patients (cases 3 and 8), and seizure frequency was once to several times a day. Twelve healthy males of the same age group (aged 6 to 34) without smoking habit and on no medication were used as controls (Tables 1 and 2 ). Peripheral blood lymphocytes were used for the detection of SCE after the bromodeoxyuridine (BrdU) labelling method (Latt 1973) . Venous blood was drawn aseptically from each subject and collected in vacutainer tubes containing sodium heparin (Becton Dickinson, Mountain View, CA, USA). Lymphocyte culture was started within four hours after sampling. 0.5 ml of heparinized blood was added to 5 ml of RPMI-1640 medium containing 10% fetal calf serum and 0.2% phytohemagglutinin. P solution (Difco, Detroit, MI, USA). After the culture was incubated at 37°C in a COZ incubator for 24 hr, BrdU (Sigma, St. Louis, MO, USA) was added to yield a final concentration of 0.4,ug/ml. It was further incubated in complete darkness for 48 hr including a final 2 hr treatment with 0.11ug/ml of colcemid (Gibco, Grand Island, NY, USA). Cells were harvested by centrifugation, resuspended in 0.075 M KCl for 30 min and fixed three times in 3: 1 methanol : acetic acid. Slides were prepared by flame-air drying, and stained by the alkaline treatment plus Giemsa technique (BrdU-AG method) described by Nakagawara et al. (1982) . That is, the preparation was stained for 5 to 10 min in a 1.8% solution of Giemsa (Merck, Darmstadt, Germany) TABLE 2. SCE frequencies in healthy controls in 1/15 M Na2HPO4 and 1/15 M KH2PO4 adjusted to pH 11.0 with 2.5 N NaOH. Only cells with 46 chromosomes were selected at random for SCE analysis. As a rule, fifty cells per individual were scored. Centromeric exchanges were included unless the chromatids were apparently twisted. The average number of SCEs was calculated individually (mean SCE per cell), and the values were compared among epileptics, non-epileptics and controls.
Kruskal-Wallis rank test and Mann-Whitney U test were used for the statistical evaluation among three groups and between each two groups, respectively.
RESULTS
The results are shown in Tables 1 and 2 , and Fig. 1 . Frequency of SCE per cell was 4.63±0.71 ( mean + s.D.) in epileptics, 4.70±0.89 in non-epileptics and 3.84 + 0.56 in healthy controls. A statistically significant difference (p <0.05) was recognised among the three groups. SCEs in both epileptics and non-epileptics were significantly higher (p <0.05) than those in controls. But no significant difference of SCE frequency between epileptics and non-epileptics. No direct correlation was noted between serum PHT/PB levels and SCE frequencies. Similarly, the age of the patients and healthy controls and the duration of AED therapy had no apparent effect on SCE frequencies. and their metabolites showed no effect on SCE frequency. Guron et al. (1985) and Schaumann et al. (1985a) reported lack of SCE induction by CBZ. Concerning the in vivo studies of AED-treated epileptic individuals, Hunke and Carpenter (1978) failed to find a significant difference between SCE rates in epileptics treated with PHT and controls, whereas Habedank et al. (1982) and Schaumann et al. (1985b) observed increased SCE rates in child and adult patients with PHT monotherapy, respectively. Kulkarni et al. (1984) reported a significant increase in SCE of epileptic patients treated PHT and/or PB as compared with controls. According to Schaumann et al. (1985a Schaumann et al. ( , 1989 , there was no significant increase of SCE in patients with CBZ or YPA monotherapy.
DISCUSSION
In our previous study (Yamamoto et al. 1987 ), we measured SCE frequencies in human lymphocytes cultured in medium containing various concentrations of PHT and PB, and in lymphocytes from epileptic and non-epileptic patients with organic brain damage due to various etiologies and healthy controls. In vitro studies revealed an increase of SCE with an elevation of either PHT and PB. However, there was no difference of SCEs between epileptics and non-epileptics, whereas SCEs in both epileptics and non-epileptics were significantly higher than those in controls.
From these observations it was suggested that AEDs, in particular PHT and PB, were suspected to possess a genotoxic effect, but there was still much room for further investigation.
One of the reasons for this uncertainty lies undoubtedly in various factors which were known to have influence on SCE frequencies (Carrano and Moore 1982; Lambert et al. 1982) . Some of the earlier reports left these factors out of consideration. The concentration of BrdU in culture medium is one of the most important ones. Because BrdU has an ability to induce SCE, the SCE frequency increases with an elevation of BrdU concentration (Carrano and Moore 1982; Lambert et al. 1982 ). This SCE-inducing effect of BrdU might make it difficult to detect a small variation of SCE. Smoking habit can be another important intervening factor. Many authors reported that smokers had a significantly higher SCE frequency than non-smokers (Carrano and Moore 1982; Lambert et al. 1982; Husum et al. 1986 ). Other possible confounding factors of SCE are age, sex (Dewdney et al. 1986; Husum et al. 1986; Wulf et al. 1986 ), drugs and chemicals (Lambert et al. 1982) , viruses (Nichols et al. 1978) , etc.
Based on the above considerations, we designed this study to exclude various confounding factors as far as possible. That is, only the subjects who fulfilled the criteria as mentioned above were selected, and we used the same standardized technique for detecting SCE including the lowest concentration (0.4,ug/ml) of BrdU which could give rise to good differential staining of sister chromatids in our laboratory.
The results were as follows : Firstly, no significant difference of SCE frequency was found between epileptics with AED therapy and non-epileptics without AED therapy. Secondly, SCE frequencies in both epileptics and nonepileptics were significantly higher than those in healthy controls.
Thus, it appears that AEDs have no evident mutagenic effect and organic brain damage per se might have an influence on the formation of SCE.
The mechanism by which this higher SCE frequency occurs in both epileptics and non-epileptics remains to be elucidated. One possible explanation for this phenomenon is that endogeneous factors such as endocrine and autonomic nervous system dysfunction associated with organic brain damage might play a part in SCE formation. In fact, Das et al. (1985) pointed out the possibility that the variation in general hormonal status during pregnancy influenced the SCE frequency in the newborn. In the present study, however, consideration was not given to the degree of functional impairment in the endocrine and autonomic nervous system. Our patients, therefore, may be heterogeneous in this respect. Furthermore, it seems likely that a relatively wide distribution of SCEs in non-epileptics may reflect this heterogeneity. More well-controlled studies will be needed before the final conclusion is made.
